Navigation Links
Kawasaki Disease Treated with Plasma-Derived Therapy
Date:1/6/2009

Patients with this Pediatric Disease Depend on Plasma Donation

ANNAPOLIS, Md., Jan. 6 /PRNewswire/ --Kawasaki disease is an uncommon illness that typically affects children between the ages of two and five and is a leading cause of acquired heart disease in children in the United States according to the American Heart Association (AHA). Kawasaki disease is treated with intravenous immune globulin (IVIG), a plasma-derived therapy that replaces vital missing antibodies in a person's plasma and that is manufactured by member companies of the Plasma Protein Therapeutics Association (PPTA).

As reported recently in the news, Backstreet Boys singer Brian Littrell's six-year-old son Baylee has been diagnosed with atypical Kawasaki disease. According to Littrell's website posting, "He received IVIG, which is a treatment to bring down the inflammation in his coronary arteries. Baylee will be closely monitored for the next 6-8 weeks by a Pediatric Cardiologist to see if the treatment was effective." Kawasaki disease can inflame and weaken coronary arteries, creating the risk of blood clots that can cause heart attacks.

"IVIG is produced from plasma donated by healthy, committed donors across the country," said Julie Birkofer, PPTA Vice President, North America. Plasma is the straw-colored, liquid portion of whole blood that remains when red blood cells, platelets and other cellular components are removed. It is rich in proteins needed to fight infection, clot blood, and ensure proper lung function.

Source plasma used to produce life-saving therapies like IVIG is donated by healthy, committed individuals at 363 government licensed and International Quality Plasma Program-certified plasma collections centers in the U.S., Europe and Canada.

"Nationwide, tens of thousands of individuals rely on plasma protein therapies to treat rare, chronic diseases and disorders, which include hemophilia and other bleeding disorders, primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, Kawasaki disease, and certain autoimmune and neurological disorders," said Birkofer. "These protein replacement therapies are life-saving."

To learn more about life-saving plasma protein therapies, visit www.pptaglobal.org. To find out how to become a plasma donor and become an important part of saving someone's life this holiday season, visit www.donatingplasma.org.

The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasmaderived and recombinant analog therapies (collectively, "plasma protein therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions, and alpha1 proteinase inhibitor used to treat people with alpha1antitrypsin deficiency, also known as genetic emphysema.


'/>"/>
SOURCE Plasma Protein Therapeutics Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jett Travolta and Kawasaki Disease: Separating Fact From Fiction
2. International research collaboration narrows focus on genetic cause of Kawasaki disease
3. Florida and California Represent Equivalent Areas of Opportunity in the Alzheimers Disease Drug Market
4. Collagen VI may help protect the brain against Alzheimers disease
5. Cell death from cytomegalovirus may bring new life to treatment of retinal disease
6. Hard To Treat Diseases (HTDS) Completes E Europe Merger
7. Parkinsons Disease Plays Havoc With Common Orthopaedic Conditions
8. Toxicity mechanism identified for Parkinsons disease
9. What is the pathogenesis of C. jejuni-related disease?
10. Gene Mutation Tied to Inherited Fatal Lung Disease
11. Hard To Treat Diseases (HTDS) Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: